| Literature DB >> 29085693 |
Constantine Theocharides1, Kyriakos Chatzopoulos1, Dimitrios Papanikolaou2, Vasileios Siokas1, Ioannis Amplianitis3, Athanasios Papanikolaou1.
Abstract
Metastases of melanoma to the urinary bladder are infrequent. Even rarer are metastases to the urinary bladder from uveal melanoma, with only 3 cases published in the literature so far. Herein we present a case of a 77-year-old male patient who presented with metastatic melanoma to the urinary bladder. The patient's history included the diagnoses of uveal melanoma treated with radiation 25 years ago, as well as that of cutaneous melanoma diagnosed 7 years ago. The molecular study of the urinary bladder tumor specimen identified mutation of the GNAQ gene, which has been suggested to be an early molecular event in the pathogenetic course of over 80% of uveal melanomas. Therefore, the diagnosis of uveal melanoma metastatic to the urinary bladder was made.Entities:
Year: 2017 PMID: 29085693 PMCID: PMC5612604 DOI: 10.1155/2017/4818537
Source DB: PubMed Journal: Case Rep Pathol ISSN: 2090-679X
Figure 1Histopathologic features of the urinary bladder tumor (a, b) and the cutaneous lesion (c, d).
Panel of antibodies used in the present case report. RTU: ready to use.
| Antibody | Clone | Company | Dilution |
|---|---|---|---|
| Anti-Melan A | A103 | BioGenex, USA | RTU |
| Anti-S100 | AR058-10R | BioGenex, USA | RTU |
| Anti-Melanosome | HMB45 | Zeta Corporation, USA | 1 : 100 |
| Anti-Vimentin | V9 | BioGenex, USA | RTU |
| Anti-Desmin | DE-R-11 | Leica Biosystems, UK | RTU |
| Anti-Chromogranin A | 5H7 | Leica Biosystems, UK | RTU |
| Anti-EMA | GP1.4 | Thermo Fisher Scientific, UK | RTU |
| Anti-CD99 | 12E7 | Leica Biosystems, UK | RTU |
| Anti-Keratin | AE1/AE3 | Zeta Corporation, USA | 1 : 100 |
Figure 2Melan A immunopositivity in the cells of the TURBT specimen.
Clinical features of the 4 cases of uveal melanoma metastases in the urinary bladder that have been reported so far in the literature.
| Publication | Age | Gender | Concurrent metastases | Years after initial uveal melanoma diagnosis | Clinical course |
|---|---|---|---|---|---|
| Moore et al. [ | 82 | Male | None | 12 | Free of disease at 9 months |
| Irisawa et al. [ | 77 | Male | Widespread | 6 | Death at 10 months |
| Wisenbaugh et al. [ | 62 | Female | Widespread | 10 | Death at 5 months |
| Present case | 77 | Male | Widespread | 25 | Widespread multiple metastases at months |